

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**FORM 8-K**

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):

November 12, 2020

---

**INTEGRATED BIOPHARMA, INC.**  
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

**DELAWARE**  
(STATE OR OTHER JURISDICTION OF INCORPORATION)

**001-31668**  
(COMMISSION FILE NUMBER)

**22-2407475**  
(I.R.S. EMPLOYER IDENTIFICATION NO.)

**225 Long Avenue**  
**Hillside, New Jersey 07205**  
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

**(973) 926-0816**  
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	None	None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 2.02. Results of Operations and Financial Condition.**

On November 12, 2020, Integrated Biopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2020. A copy of the press release is furnished as Exhibit 99.1 hereto and is hereby incorporated by reference into this Item 2.02.

The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

99.1 [Press Release dated November 12, 2020](#)

**EXHIBIT INDEX**

<b>Exhibit</b>	<b>Description</b>
99.1	<a href="#">Press Release dated November 12, 2020</a>

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**INTEGRATED BIOPHARMA, INC.**

Date: November 12, 2020

By: /s/ Riva Sheppard  
Riva Sheppard  
Co-Chief Executive Officer





**Integrated BioPharma Reports Results for its Quarter Ended September 30, 2020**

HILLSIDE, NEW JERSEY (November 12, 2020) - Integrated BioPharma, Inc. (OTC QB: INBP) (the "Company") reports its financial results for the quarter ended September 30, 2020.

Revenue for the quarter ended September 30, 2020 was \$15.2 million compared to \$11.4 million for the quarter ended September 30, 2019, an increase of \$3.8 million or 33.0%. The Company had operating income for the quarter ended September 30, 2020 of \$1.5 million compared to operating income of \$0.5 million for the quarter ended September 30, 2019.

For the quarter ended September 30, 2020, the Company had net income of \$1.0 million or \$0.04 per share of common stock, compared with net income of \$0.3 million or \$0.01 per share of common stock for the quarter ended September 30, 2019. The Company's diluted net income per share of common stock for the quarters ended September 30, 2020 and 2019 were \$0.03 and \$0.01 per share of common stock, respectively.

"We are excited to report that our revenue increased by approximately 33% in the quarter ended September 30, 2020 from the prior quarter ended September 30, 2019 and that our revenue from our two significant customers in our Contract Manufacturing Segment remained consistent; representing approximately 92% and 91% of total revenue in the quarters ended September 30, 2020 and 2019, respectively," stated the Co-Chief Executive Officers of the Company, Riva Sheppard and Christina Kay.

Mrs. Sheppard and Ms. Kay further stated, "we are also pleased that Eric Friedman has filled the vacancy on our Board of Directors as a Class III director and look forward to working with him as a member of our Board of Directors."

---

A summary of our financial results for the quarter ended September 30, 2020 and 2019 follows:

**INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF INCOME**  
(In thousands, except share and per share amounts)  
(unaudited)

	<b>Fiscal Year Ended</b>	
	<b>September 30,</b>	
	2020	2019
Total revenue	\$ 15,172	\$ 11,406
Cost of sales	12,799	10,007
Gross profit	2,373	1,399
Selling and administrative expenses	864	923
Operating income	1,509	476
Other expense, net <sup>(1)</sup>	(41)	(127)
Income before income taxes	1,468	349
Income tax expense, net	427	37
Net income	\$ 1,041	\$ 312
Net income per common share:		
Basic	\$ 0.04	\$ 0.01
Diluted	\$ 0.03	\$ 0.01
Weighted average common shares outstanding:		
Basic	29,645,943	29,565,943
Diluted	31,713,076	30,724,633

(1) Includes interest expense of \$76 and \$124, respectively.

About Integrated BioPharma Inc. (INBP)

Integrated BioPharma, Inc. is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at [www.ibiopharma.com](http://www.ibiopharma.com).

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “should,” “would,” “strategy,” “plan” and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include developments in the market and related products and services, risks associate with the outbreak and continued spread of COVID-19 and other risks and uncertainties described in the section entitled “Risk Factors” in INBP’s most recent Annual Report on Form 10-K. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.